Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026

Regulatoryinjectable iron medicinesNeutral

AI Analysis

Summary

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a safety review of injectable iron medicines to assess the risk of low blood phosphate levels and related bone problems. This is a routine ongoing safety signal assessment.

Outcome Details

Safety review of injectable iron medicines for risk of low blood phosphate levels and related bone problems

Importance:4/10

Sentiment:

0.00

EMAPRACsafety reviewinjectable ironphosphate levelsbone problems

Read the original article

Published by EMA News on September 4, 2026 12:00 PM

Read Original